Akero Therapeutics' drug, efruxifermin, demonstrated significant reduction in liver scarring after nearly two years in a mid-stage study for metabolic dysfunction-associated steatohepatitis (MASH) patients. The drug showed superior benefits compared to other treatments, with potential peak sales of $2-3 billion. Confirmation in a late-stage trial is required. NASH affects over 17 million Americans, with no approved drugs currently available.
他の言語に翻訳
原文コンテンツから
www.medscape.com
抽出されたキーインサイト
by Leroy 場所 www.medscape.com 03-04-2024
https://www.medscape.com/s/viewarticle/akeros-fatty-liver-disease-drug-lessens-scarring-mid-stage-2024a1000450深掘り質問